X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1595) 1595
Newsletter (101) 101
Newspaper Article (23) 23
Book Chapter (11) 11
Publication (2) 2
Reference (2) 2
Transcript (2) 2
Book / eBook (1) 1
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
panitumumab (1632) 1632
cetuximab (968) 968
humans (965) 965
oncology (852) 852
colorectal cancer (820) 820
chemotherapy (591) 591
colorectal neoplasms - drug therapy (547) 547
cancer (508) 508
female (435) 435
male (417) 417
1st-line treatment (397) 397
colorectal neoplasms - genetics (391) 391
metastasis (387) 387
colorectal neoplasms - pathology (369) 369
middle aged (368) 368
mutation (365) 365
aged (340) 340
bevacizumab (333) 333
kras (330) 330
fluorouracil (324) 324
antibodies, monoclonal - therapeutic use (310) 310
care and treatment (295) 295
antineoplastic agents - therapeutic use (277) 277
adult (265) 265
egfr (262) 262
antineoplastic combined chemotherapy protocols - therapeutic use (258) 258
research (253) 253
epidermal growth factor (251) 251
leucovorin (250) 250
oxaliplatin (249) 249
ras proteins - genetics (245) 245
receptor, epidermal growth factor - antagonists & inhibitors (235) 235
growth-factor receptor (222) 222
open-label (216) 216
treatment outcome (212) 212
neoplasm metastasis (210) 210
proto-oncogene proteins p21 (209) 209
metastatic colorectal cancer (205) 205
monoclonal antibodies (205) 205
proto-oncogene proteins - genetics (205) 205
phase-iii trial (194) 194
aged, 80 and over (184) 184
therapy (183) 183
antibodies, monoclonal - administration & dosage (177) 177
tumors (177) 177
pharmacology & pharmacy (172) 172
survival (166) 166
drug therapy (165) 165
metastatic colorectal-cancer (164) 164
genetic aspects (163) 163
disease-free survival (162) 162
prognosis (161) 161
analysis (160) 160
antibodies, monoclonal, humanized (158) 158
irinotecan (157) 157
proto-oncogene proteins b-raf - genetics (157) 157
cetuximab plus irinotecan (154) 154
braf (143) 143
medicine & public health (143) 143
health aspects (133) 133
cancer therapies (132) 132
colorectal carcinoma (128) 128
patients (124) 124
animals (123) 123
antibodies, monoclonal - adverse effects (122) 122
digestive system diseases (120) 120
ras mutations (120) 120
phase-iii (116) 116
epidermal growth factor receptor (115) 115
trial (114) 114
colorectal neoplasms - mortality (112) 112
expression (112) 112
efficacy (111) 111
hematology, oncology and palliative medicine (109) 109
clinical trials (108) 108
metastases (108) 108
antineoplastic agents (106) 106
oncology, experimental (104) 104
monoclonal-antibody (101) 101
retrospective studies (97) 97
antineoplastic agents - pharmacology (96) 96
camptothecin - analogs & derivatives (96) 96
erbb receptors - antagonists & inhibitors (96) 96
antimitotic agents (95) 95
cancer patients (95) 95
biomarkers (93) 93
neoplasms (93) 93
antineoplastic agents - adverse effects (92) 92
cell line, tumor (92) 92
receptor, epidermal growth factor - metabolism (92) 92
antibodies, monoclonal - pharmacology (91) 91
mutations (91) 91
biomarkers, tumor - genetics (89) 89
gene mutations (89) 89
proto-oncogene proteins p21 - genetics (89) 89
colorectal neoplasms - metabolism (88) 88
plus irinotecan (86) 86
gefitinib (85) 85
resistance (84) 84
surgery (83) 83
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1654) 1654
French (27) 27
Japanese (23) 23
German (19) 19
Spanish (13) 13
Russian (6) 6
Czech (4) 4
Hungarian (3) 3
Korean (3) 3
Chinese (2) 2
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Nature (London), ISSN 1476-4687, 2012, Volume 486, Issue 7404, pp. 532 - 536
Journal Article
International journal of cancer, ISSN 0020-7136, 2019, Volume 145, Issue 2, pp. 576 - 585
Panitumumab is approved for RAS wild‐type metastatic colorectal cancer and was evaluated in Phase III (PRIME, NCT00364013) and Phase II (PEAK, NCT00819780)... 
toxicity | metastatic colorectal cancer | panitumumab | maintenance | epidermal growth factor receptor | survival | 1ST-LINE TREATMENT | BEVACIZUMAB | CHEMOTHERAPY PLUS | PHASE-III TRIAL | NON-INFERIORITY | CETUXIMAB | THERAPY | ONCOLOGY | END-POINTS | KRAS | MUTATIONS | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | Humans | Middle Aged | Male | Oxaliplatin - therapeutic use | Fluorouracil - therapeutic use | Clinical Trials, Phase III as Topic | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Panitumumab - therapeutic use | Maintenance Chemotherapy | Oxaliplatin - administration & dosage | Retrospective Studies | Bevacizumab - administration & dosage | Treatment Outcome | Randomized Controlled Trials as Topic | Panitumumab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Organoplatinum Compounds - therapeutic use | Clinical Trials, Phase II as Topic | Epidermal growth factor | Metastasis | Consulting services | Analysis | Panitumumab | Colorectal cancer | Toxicity | Colorectal carcinoma | Clinical trials | Diarrhea | Maintenance | Survival | Bevacizumab | Metastases | Confidence intervals | Randomization | Oxaliplatin | Cancer | Index Medicus | Life Sciences | Cancer Therapy and Prevention
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 2015, Volume 51, Issue 13, pp. 1704 - 1713
Journal Article
Journal Article
Advances in therapy, ISSN 1865-8652, 2019, Volume 36, Issue 3, pp. 670 - 683
This study aimed to better understand panitumumab use in real-life clinical practice in first- and second-line treatment of metastatic colorectal cancer in... 
Tumor location | Observational study | Panitumumab | Rheumatology | Real-world data | Internal Medicine | Oncology | RAS wild-type | Medicine & Public Health | Cardiology | Pharmacology/Toxicology | Endocrinology | Metastatic colorectal cancer | MEDICINE, RESEARCH & EXPERIMENTAL | 1ST-LINE TREATMENT | FLUOROURACIL | METASTATIC COLORECTAL-CANCER | FOLFIRI | TRIAL | SKIN TOXICITY | RANDOMIZED PHASE-III | 2ND-LINE TREATMENT | PHARMACOLOGY & PHARMACY | KRAS | PLUS | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | ras Proteins - biosynthesis | Fluorouracil - therapeutic use | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Camptothecin - administration & dosage | Female | Leucovorin - therapeutic use | Panitumumab - therapeutic use | Camptothecin - analogs & derivatives | Panitumumab - adverse effects | Camptothecin - adverse effects | Camptothecin - therapeutic use | Europe | Panitumumab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Cohort Studies | Health technology assessment | Original Research
Journal Article
Molecular Oncology, ISSN 1574-7891, 09/2014, Volume 8, Issue 6, pp. 1084 - 1094
Cetuximab and panitumumab are anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies used as therapies for metastatic colorectal cancer... 
Acquired resistance | RAS | Panitumumab | Colorectal cancer | Cetuximab | Anti-EGFR therapy | MET
Journal Article
Journal Article
Cancer Research, ISSN 0008-5472, 09/2018, Volume 78, Issue 17, pp. 5144 - 5154
For many solid tumors, surgical resection remains the gold standard and tumor-involved margins are associated with poor clinical outcomes. Near-infrared (NIR)... 
PANITUMUMAB | SURGERY | HEAD | ONCOLOGY | EGF | ANTIBODY | ALPHA | GROWTH-FACTOR | NECK-CANCER | clinical trial | image-guided surgery | near-infrared imaging | head and neck cancer | fluorescence
Journal Article